Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Tissue engineering in the rheumatic diseases

Figure 2

Cartilage tissue engineering with mesenchymal stem cells (MSCs) derived from osteoarthritis (OA) patients. Human MSCs were isolated and expanded from femoral heads of five OA patients undergoing endoprothetic joint replacement. (a) Two and a half million MSCs per 100 μL were embedded in fibrinogen PLGA fleeces and chondrogenically induced with transforming growth factor-beta-3. (b) At day 14, propidium iodide/fluorescein diacetate staining revealed a high cell viability (green cells) and homogenous cell distribution. Remaining PLGA fibers appeared red. (c) After 4 weeks, matrix formation was demonstrated by alcian blue staining of cartilage proteoglycans and by antibody staining of (d) collagen type I and (e) cartilage-specific collagen type II. (f) Negative IgG control. In summary, we found no differences between MSCs derived from healthy donors and those from patients with OA. PLGA, poly(DL-lactic acid-co-glycolic acid).

Back to article page